Skip to main content
SpringerLink
Log in

Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma

  • Case Report
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We herein report a case of malignant lymphoma that showed differential FDG accumulation associated with the degree of glucose transporter 1 (GLUT-1) expression. For clinical staging purpose, FDG-PET was performed on a 47-year-old male who had been diagnosed to have malignant lymphoma, diffuse medium B-cell type. Although an X-ray CT showed multiple and bulky lymphadenopathy including bilateral submandibular, deep cervical, supraclavicular, axillar, hilar, mesenteric and paraaortic regions, FDG-PET showed a high accumulation only in the bilateral submandibular and deep cervical region. An immunohistochemical analysis demonstrated a high GLUT-1 expression in the right cervical lymph, node, which showed a high FDG uptake. On the other hand, a bone marrow specimen with diffuse lymphoma cell involvement indicated showed no FDG accumulation and also revealed a negative GLUT-1 expression. This case suggests that the differential FDG accumulation shown by lesions is associated with the degree of GLUT-1 expression in patients with lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.J Nucl Med 1987; 28: 288–292.

    PubMed  CAS  Google Scholar 

  2. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.J Nucl Med 1991; 32: 686–691.

    PubMed  CAS  Google Scholar 

  3. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[18F]-fluoro-2-deoxy-d-glucose: correlation with CT.Radiology 1994; 190: 111–116.

    PubMed  CAS  Google Scholar 

  4. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18) fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma.Cancer 2001; 91: 889–899.

    Article  PubMed  CAS  Google Scholar 

  5. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.J Nucl Med 1997; 38: 343–348.

    PubMed  CAS  Google Scholar 

  6. Moog F, Bangerter M, Diederichs CGA, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[18-F]fluoro-d-glucose (FDG) PET in nodal staging.Radiology 1997; 203: 795–800.

    PubMed  CAS  Google Scholar 

  7. Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann HC, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.Eur J Nucl Med 1998; 25: 721–728.

    Article  PubMed  CAS  Google Scholar 

  8. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.Ann Oncol 1998; 9: 1117–1122.

    Article  PubMed  CAS  Google Scholar 

  9. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, et al. Whole-body18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.Nucl Med Commun 1999; 20: 13–20.

    Article  PubMed  CAS  Google Scholar 

  10. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).Ann Oncol 2001; 12: 825–830.

    Article  PubMed  CAS  Google Scholar 

  11. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.Ann Nucl Med 2002; 16: 337–345.

    Article  PubMed  Google Scholar 

  12. Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas.Br J Radiol 2000; 73: 482–487.

    PubMed  CAS  Google Scholar 

  13. Schöder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, et al. Effect of whole-body18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.J Nucl Med 2001; 42: 1139–1143.

    PubMed  Google Scholar 

  14. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.Blood 1998; 91: 4464–4471.

    PubMed  Google Scholar 

  15. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisery MN.18FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma—comparison with CT.Leukemia and Lymphoma 2000; 39: 5–6.

    Google Scholar 

  16. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F] FDG-PET a valid alternative to conventional diagnostic methods?J Clin Oncol 2001; 19: 414–419.

    PubMed  CAS  Google Scholar 

  17. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.J Nucl Med 1992; 33: 325–329.

    PubMed  CAS  Google Scholar 

  18. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma.J Nucl Med 1995; 36: 1790–1796.

    PubMed  CAS  Google Scholar 

  19. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.Blood 1995; 86: 3522–3527.

    PubMed  CAS  Google Scholar 

  20. Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose (18F-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.Ann Oncol 1999; 10: 1185–1189.

    Article  PubMed  CAS  Google Scholar 

  21. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.J Nucl Med 1999; 40: 556–565.

    PubMed  CAS  Google Scholar 

  22. Smith DAT. The rate-limiting step for tumor [18F] fluoro-2-deoxy-d-glucose (FDG) incorporation.Nucl Med Biol 2001; 28: 1–4.

    Article  PubMed  CAS  Google Scholar 

  23. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cellsin vitro.Nucl Med Biol 1998; 25: 593–597.

    Article  PubMed  CAS  Google Scholar 

  24. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al.In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.J Nucl Med 1995; 36: 1811–1817.

    PubMed  CAS  Google Scholar 

  25. Warburg OH.The metabolism of tumors. London; Constable, 1930: 29–169.

    Google Scholar 

  26. Shinohara Y. Identification and characterization of hexokinase isoform predominantly expressed in malignant tumor cells.Yakugaku Zasshi 2000; 130: 657–666. [Japanese]

    Google Scholar 

  27. Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells.Hum Gene Ther 1999; 10: 155–164.

    Article  PubMed  CAS  Google Scholar 

  28. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer.Nucl Med Biol 2002; 29: 443–453.

    Article  PubMed  CAS  Google Scholar 

  29. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.J Nucl Med 2002; 43: 173–180.

    PubMed  CAS  Google Scholar 

  30. Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to3H-2-deoxyglucose retention in murine tumor models.Nucl Med Biol 1996; 23: 533–541.

    Article  PubMed  CAS  Google Scholar 

  31. Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, et al. Whole-body hybrid PET with18F-FDG in the staging of non-Hodgkin's lymphoma.J Nucl Med 2001; 42: 601–608.

    PubMed  CAS  Google Scholar 

  32. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models.J Nucl Med 2001; 42: 1551–1555.

    PubMed  CAS  Google Scholar 

  33. Mueckler M. Facilitative glucose transporters.Eur J Biochem 1994; 219: 713–725.

    Article  PubMed  CAS  Google Scholar 

  34. Adams V, Kempf W, Hassam S, Briner J. Determination of hexokinase isozyme I and II by RT-PCR: increased hexokinase II isozyme in human renal cell carcinoma.J Biochem Mol Med 1995; 54: 53–58.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, 812-8582, Fukuoka, Japan

    Hirofumi Koga, Yoshio Matsuo, Masayuki Sasaki, Makoto Nakagawa, Koichiro Kaneko, Kazutaka Hayashi, Yasuo Kuwabara & Hiroshi Honda

Authors
  1. Hirofumi Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshio Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayuki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koichiro Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazutaka Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Kuwabara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirofumi Koga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koga, H., Matsuo, Y., Sasaki, M. et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 17, 327–331 (2003). https://doi.org/10.1007/BF02988530

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02988530

Key words

Search

Navigation